IRadimed Corporation
IRadimed Corporation (IRMD) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
irmd · stock forecast · 2 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$120
Consensus
$120
+27.2% upside
Low
$120
Median: $120 · Last Close: $94.34
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $95.90 | ↑ 1.66% |
1-day model range: $95.55–$96.26. Peak: $96.26 (+1.66%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $117 | +24.1% |
| 2028 | $133 | +40.5% |
| 2029 | $142 | +50.8% |
| 2030 | $148 | +56.8% |
| 2031 | — | +60.3% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IRMD · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-02-14 | Roth MKM | Maintains | Buy→Buy |
| 2024-08-02 | Roth MKM | Maintains | Buy→Buy |
| 2021-08-02 | Roth Capital | Maintains | Buy→Buy |
| 2017-07-31 | Roth Capital | Upgrade ↑ | Neutral→Buy |
| 2016-10-05 | Roth Capital | Downgrade ↓ | Buy→Neutral |
| 2016-04-04 | Roth Capital | Maintains | Buy→Buy |
| 2015-06-16 | Roth Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on IRadimed Corporation (IRMD) stock. Of the recent 7 rating actions, 1 were upgrades and 1 were downgrades. 2 analysts currently cover IRMD.
Analyst Recommendation Trends
IRMD analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$91M
↓ 19.0% YoY
Revenue Next Year
$101M
↑ 10.6% YoY
EPS This Year
$2.08
EPS Next Year
$2.35
↑ 13.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast IRMD EPS of $2.08 for the current fiscal year, based on estimates from 1 analysts. The IRMD revenue forecast is $91M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IRMD stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IRMD price target is $120.00 (+27.2% upside), with an analyst consensus of Buy.
The IRMD short-term stock prediction for tomorrow is $95.90 (+1.66%). The IRMD stock price prediction for 2027 estimates an average of $117. The IRMD stock prediction for 2030 projects a range of $142–$154.
IRadimed Corporation trades on NASDAQ under the ticker IRMD. The IRMD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
IRMD forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month IRMD price target is $120.00, with a high forecast of $120.00 and a low of $120.00. The median price target is shown in the chart above when available. This implies +27.2% potential upside from the current price of $94.34.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.